Business
(Reuters) – All regulatory final prerequisites associated with Novo Holdings’ $16.5 billion acquisition of U.S. contract drug maker Catalent (NYSE:) have been fulfilled, the...
Hi, what are you looking for?
(Reuters) – All regulatory final prerequisites associated with Novo Holdings’ $16.5 billion acquisition of U.S. contract drug maker Catalent (NYSE:) have been fulfilled, the...